Genta, Inc. (GNTA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA)

GNTA 1.924

-2.3%

Dec 2 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ken Brynjolfsson who wrote (1172)	5/17/1999 10:36:00 AM
From: bob zagorin	of 1870

Excerpts from one ASCO abstracts published thru Medscape this a.m. "...Preclinical Ideas and New Agents There is a significant preclinical rationale for the treatment of chemotherapy-resistant cells with inhibitors of Bcl-2. Dr. Jansen and colleagues[11] showed that a 2-week continuous infusion of a Bcl-2 antisense construct was well tolerated, resulted in reduced Bcl-2 levels, and also induced clinical regression in some lesions..." "...[11]Jansen B, Wacheck V, Heere-Ress E, et al: A phase I-II study with dacarbazine and BCL-2 antisense oligonucleotide G3139 (GENTA) as a chemosensitizer in patients with advanced malignant melanoma [Abstract 2049]. American Society of Clinical Oncology 35th Annual Meeting, Atlanta, 1999..."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next